$0.905000
-0.03-2.79%
At Close: -
$0.923800
0.022.08%
After Hours: 6:07 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Citius Pharma (NASDAQ:CTXR) Stock, Analyst Ratings, Price Targets, Forecasts
Citius Pharmaceuticals Inc has a consensus price target of $4.67 based on the ratings of 3 analysts. The high is $6 issued by EF Hutton on July 15, 2024. The low is $4 issued by HC Wainwright & Co. on May 31, 2024. The 3 most-recent analyst ratings were released by EF Hutton, HC Wainwright & Co., and HC Wainwright & Co. on July 15, 2024, May 31, 2024, and February 14, 2024, respectively. With an average price target of $4.67 between EF Hutton, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 405.16% upside for Citius Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
EF Hutton
HC Wainwright & Co.
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Citius Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/15/2024 | Buy Now | 549.49% | EF Hutton | Jason Kolbert | → $6 | Initiates | → Buy | Get Alert |
| 05/31/2024 | Buy Now | 332.99% | HC Wainwright & Co. | Vernon Bernardino | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 02/14/2024 | Buy Now | 332.99% | HC Wainwright & Co. | Vernon Bernardino | → $4 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 332.99% | HC Wainwright & Co. | Vernon Bernardino | → $4 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 332.99% | HC Wainwright & Co. | Vernon Bernardino | $6 → $4 | Maintains | Buy | Get Alert |
| 05/30/2023 | Buy Now | 549.49% | HC Wainwright & Co. | Vernon Bernardino | → $6 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | Buy Now | 549.49% | HC Wainwright & Co. | Vernon Bernardino | → $6 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 549.49% | HC Wainwright & Co. | Vernon Bernardino | → $6 | Reiterates | → Buy | Get Alert |
| 01/18/2022 | Buy Now | 549.49% | HC Wainwright & Co. | Vernon Bernardino | $4 → $6 | Maintains | Buy | Get Alert |
| 11/30/2021 | Buy Now | 332.99% | Maxim Group | Michael Okunewitch | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Citius Pharma (CTXR) stock?
The latest price target for Citius Pharma (NASDAQ:CTXR) was reported by EF Hutton on July 15, 2024. The analyst firm set a price target for $6.00 expecting CTXR to rise to within 12 months (a possible 549.49% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Citius Pharma (CTXR)?
The latest analyst rating for Citius Pharma (NASDAQ:CTXR) was provided by EF Hutton, and Citius Pharma initiated their buy rating.
When was the last upgrade for Citius Pharma (CTXR)?
There is no last upgrade for Citius Pharma
When was the last downgrade for Citius Pharma (CTXR)?
There is no last downgrade for Citius Pharma.
When is the next analyst rating going to be posted or updated for Citius Pharma (CTXR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Pharma was filed on July 15, 2024 so you should expect the next rating to be made available sometime around July 15, 2025.
Is the Analyst Rating Citius Pharma (CTXR) correct?
While ratings are subjective and will change, the latest Citius Pharma (CTXR) rating was a initiated with a price target of $0.00 to $6.00. The current price Citius Pharma (CTXR) is trading at is $0.92, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.